The bags in question have a best-before date of January 2026.

The figures also show 8,511 failed asylum seekers were returned in this period but they do not say how many were enforced or voluntary.Separate government figures from January to March gave a fuller breakdown showing many of those who did leave voluntarily did so without government assistance or even its knowledge at the time,

This is despite repeated claims from ministers that the government has "removed" or even "deported" this many people.The Home Office says all returns outcomes are the result of collective efforts by the department.The US has dismantled large parts of a camp built to house migrants at the Guantanamo Bay Naval Base, satellite images reviewed by BBC Verify show.

President Donald Trump ordered the existing facility in Cuba be expanded to hold 30,000 migrants shortly after taking office in January. However, only a small number were ever actually held at the base.The Pentagon spent around $38m (£28.7m) on deportation and detention operations at Guantanamo Bay in the first month of operations this year alone, a Department of Defense official said.

But new images now show that around two-thirds of the roughly 260 tents installed as part of the operation had been removed as of 16 April.

When asked about the removal of the tents, a US defence official said: "This force adjustment represents a deliberate and efficient use of resources - not a reduction in readiness."Half of women with breast cancer fuelled by the hormone oestrogen are likely to see their life expectancy double when capivasertib is combined with hormone therapy, research has shown.

Prof Rob Jones, who co-led a study looking at capivasertib's effectiveness, said the drug offered "a real life impact for people to spend extra time with their relatives, with their friends".Breast cancer is the most common cancer in the UK, with one in seven women affected in their lifetimes and 75% surviving for 10 years or more after diagnosis.

In Wales, more than 2,000 people are diagnosed with breast cancer every year.Capivasertib, which was developed by experts at Velindre Cancer Centre and Cardiff University, became available to breast cancer patients on the NHS in April.